Companies › Aptabio Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Ophthalmology, Oncology, Metabolic and endocrine; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Isuzinaxib Sphingosine-1-phosphate receptor 1 (S1PR1) modulator | S1PR1 | Phase 2 | Diabetic Kidney Disease (DKD) | Jun 2027 |
| ABF-101 | – | Phase 1 | Age Related Macular Degeneration (ARMD) | Nov 2027 |
| APX-343A | – | Phase 1 | Advanced Solid Cancer | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06962098 | Isuzinaxib | Phase 2 | Diabetic Kidney Disease (DKD) | Metabolic and endocrine | Jun 2027 |
| NCT07330674 | ABF-101 | Phase 1 | Age Related Macular Degeneration (ARMD) | Ophthalmology | Nov 2027 |
| NCT07123415 | APX-343A | Phase 1 | Advanced Solid Cancer | Oncology | Oct 2028 |
Novartis Viatris Innovation Boehringer Ingelheim Vanda Pharmaceuticals Bristol-Myers Squibb Pfizer Priothera SAS
Priothera SAS Laekna Biojiva C Ray Therapeutics Innovent Biologics Technology Limited (Shanghai R&D Center)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.